Arrowhead now continues to advance plozasiran toward potential regulatory approval in severe hypertriglyceridemia. ・A possible approval will place Arrowhead directly against Ionis Pharmaceuticals, ...

Late-stage studies achieve all primary and secondary goals Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) shares jumped 18% on ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced topline results for the global Phase 3 SHASTA-3 and SHASTA-4 clinical studies of plozasiran in patients with severe hypertriglyceridemia ...

Ionis Pharmaceuticals' shares are down more than 27% so far this year. What does Cathie Wood see that others are missing?

Less than a month after Ionis Pharmaceuticals scored an FDA expansion for Tryngolza to become the first drug to specifically ...

Earlier this week, Ionis Pharmaceuticals reported that the FDA approved Tryngolza (olezarsen) to reduce triglycerides and the risk of acute pancreatitis in adults with severe hypertriglyceridemia, ...

Amarin Corporation plc (NASDAQ: AMRN) , a company committed to advancing the science of cardiovascular disease worldwide, applauds the recent FDA approval of injectable apolipoprotein C-III (APOC3) ...

Plasma triglyceride (TG) concentration reflects circulating triglyceride-rich lipoproteins and their metabolic remnants (predominantly chylomicrons, very low-density lipoprotein (VLDL) and ...

September 10, 2012 (Chevy Chase, Maryland) — Adults should be screened for high triglyceride levels once every five years because of the potential risk of cardiovascular disease and pancreatitis ...

The following is an edited, translated transcript of a conversation between Boris Hansel, MD, endocrinologist-nutritionist, and Philippe Giral, MD, PhD, a lipid management specialist, in Paris, France ...